- Cart - 0 item(s)
- $0.00
Your shopping cart is empty!
- Chemistry
- Bioactive Molecules
- Anti-infection
- Apoptosis
- Autophagy
- Cell Cycle/DNA Damage
- Cytoskeleton
- Epigenetics
- GPCR/G Protein
- Immunology/Inflammation
- JAK/STAT Signaling
- MAPK/ERK Pathway
- Membrane Transporter/Ion Channel
- Metabolic Enzyme/Protease
- Neuronal Signaling
- NF-κB
- PI3K/Akt/mTOR
- PROTAC
- Protein Tyrosine Kinase/RTK
- Stem Cell/Wnt
- TGF-beta/Smad
- Vitamin D Related/Nuclear Receptor
- Others
- Methylation
- Cytoskeletal Signaling
- Natural Products
- Alkaloids
- Amino acid
- Anthraquinones
- Cerebrosides
- Chalcones
- Coumarins
- Diterpenoids
- Flavonoids
- Iridoids
- Lignans
- Lipids
- Miscellaneous
- Monoterpenoids
- Other terpenes
- Phenols
- Phenylpropanoids
- Quinones
- Saccharides
- Sesquiterpenoids
- Steroids
- Tetraterpenoids
- Thiophenes
- Triterpenoids
- Xanthones
- Polyphenols
- Stibene glucosides
- Oligose
- Anthocyanins
- Miscellaneous
- Chromones
- Terpenoids
- Indoles
- Procyanidins
- Aliphatics
- Botanical Cyclopeptides
- ADCs
- Antibodies
- Multiplex IHC
- Material Science
- Others
[CAS NO. 1440796-75-7] Opiranserin hydrochloride
| Ships within | Stock | Price | Qty | Total |
Please click "REQUEST A QUOTE" button if there is no stock, or you need other sizes or custom synthesis.
| Catalog: | HY-109067A |
| Brand: | MCE |
| CAS: | 1440796-75-7 |
Overview
| MDL | - |
|---|---|
| Molecular Weight | 430.97 |
| Molecular Formula | C21H35ClN2O5 |
| SMILES | O=C(C1=CC(OC)=C(OCCCC)C(OC)=C1)NCC2(CCOCC2)N(C)C.[H]Cl |
Summary
Opiranserin (VVZ-149) hydrochloride, a non-opioid and non-NSAID analgesic candidate, is a dual antagonist of glycine transporter type 2 (GlyT2) and serotonin receptor 2A (5HT2A) , with IC 50 s of 0.86 and 1.3 μM, respectively. Opiranserin hydrochloride shows antagonistic activity on rP2X3 (IC 50 =0.87 μM). Opiranserin hydrochloride is development as an injectable agent for the treatment of postoperative pain [1] [2] [3] .
IC50 & Target
|
GlyT2 0.86 μM (IC 50 ) |
rP2X3 0.87 μM (IC 50 ) |
5-HT 2A Receptor 1.3 μM (IC 50 ) |
Clinical Trial
| NCT Number | Sponsor | Condition | Start Date | Phase |
|---|---|---|---|---|
| NCT02489526 | Vivozon, Inc. |
Post-Operative Pain
|
September 28, 2015 | Phase 2 |
| NCT02992041 | Vivozon, Inc. |
Post-Operative Pain
|
December 27, 2016 | Phase 2 |
| NCT03347266 | Vivozon, Inc. |
Post-Operative Pain
|
December 20, 2017 | Phase 2 |
| NCT03997812 | Vivozon, Inc. |
Pain, Postoperative
|
May 23, 2019 | Phase 2 |
| NCT02644421 | Brigham and Women´s Hospital |
Radiculopathy|Sciatica
|
November 2015 | Phase 1 |
| NCT02522598 | Vivozon, Inc. |
Post-Operative Pain
|
August 2015 | Phase 2 |
| NCT02844725 | Vivozon, Inc. |
Post-Operative Pain
|
June 2016 | Phase 2 |
| NCT03997838 | Vivozon, Inc. |
Pain, Postoperative
|
May 23, 2019 | Phase 3 |
| NCT01905410 | Vivozon, Inc. |
Healthy
|
July 2013 | Phase 1 |
| NCT02333318 | Vivozon, Inc. |
Healthy
|
July 2014 | Phase 1 |
| NCT04430088 | Vivozon, Inc. |
Pain, Postoperative
|
June 26, 2020 | Phase 3 |
Appearance
Solid
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
| Powder | -20°C | 3 years |
|---|---|---|
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month |
Solvent & Solubility
DMSO : 50 mg/mL ( 116.02 mM ; Need ultrasonic)
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 2.3203 mL | 11.6017 mL | 23.2035 mL |
| 5 mM | 0.4641 mL | 2.3203 mL | 4.6407 mL |
| 10 mM | 0.2320 mL | 1.1602 mL | 2.3203 mL |
References
- [1] Oh J, et al. Safety, Tolerability, and Pharmacokinetic Characteristics of a Novel Nonopioid Analgesic, VVZ-149 Injections in Healthy Volunteers: A First-in-Class, First-in-Human Study. J Clin Pharmacol. 2018 Jan;58(1):64-73.
- [2] Nedeljkovic SS, et al. Randomised, double-blind, parallel group, placebo-controlled study to evaluate the analgesic efficacy and safety of VVZ-149 injections for postoperative pain following laparoscopic colorectal surgery. BMJ Open. 2017 Feb 17;7(2):e011
- [3] Pang MH, et al. A series of case studies: practical methodology for identifying antinociceptive multi-target drugs. Drug Discov Today. 2012 May;17(9-10):425-34.
Arctom is a premier supply platform offering over 600K unique items of Building Blocks, Bioactive Molecules, Natural Products, ADC PEG Linkers, Antibodies, and other Research Chemicals for global pharmaceutical, biotech, university, and industrial customers. We accelerate your research by providing better and faster purchasing experience & services.